Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
62,985.30 +3,710.81 (+6.26%) CMC Crypto 200
1,359.39 +82.41 (+6.45%)
Clarivate Plc (CLVT-PA)
After hours:
| Previous close | 27.84 |
| Open | 28.45 |
| Bid | 27.57 x 800 |
| Ask | 27.73 x 800 |
| Day's range | 27.44 - 28.45 |
| 52-week range | 26.41 - 42.97 |
| Volume | |
| Avg. volume | 57,599 |
| Market cap | N/A |
| Beta (5Y monthly) | 1.24 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 5.25 (19.04%) |
| Ex-dividend date | 14 May 2024 |
| 1y target est | N/A |
- PR Newswire
Clarivate Enhances Cortellis CMC Intelligence with Post-Approval Module to Accelerate Regulatory Success
Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of the newly enhanced Cortellis CMC Intelligence™ solution, featuring a new post-approval variations module. The module for post-approval variations covers regulatory changes across multiple countries, offering meticulously curated requirements to streamline tracking. With this update, pharmaceutical, biotech, and generics companies can effortlessly navigate the regulatory process and
- PR Newswire
Clarivate Declares Dividend on Mandatory Convertible Preferred Shares
Clarivate Plc (NYSE: CLVT; CLVT PR A) ("Clarivate"), a leading global provider of transformative intelligence, today announced that its board of directors declared a quarterly dividend of $1.3125 per share on its 5.25% Series A Mandatory Convertible Preferred Shares (the "Preferred Shares"), payable in cash on June 3, 2024 to shareholders of record at the close of business on May 15, 2024.
- CNW Group
BioWorld by Clarivate Explores the Future of CAR T Therapy in Mainland China in Special Report
BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, explores the growing investment in CAR T therapy development in mainland China in a new series titled "China's CAR T market comes of age." The report examines the dynamic realm of CAR T-cell therapies in China, including the rapid pipeline growth, deals, clinical trials and challenging issues surrounding patient access to very expensive and effective cancer therapeutics.
